Global antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study
Restricted accessResearch articleFirst published online June, 2020
Global antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study
This study aimed to assess prospectively the role of anti-ß2-glycoprotein I domain I antibody (aß2GPI-DI) and the Global Antiphospholipid Syndrome Score (GAPSS) in identifying antiphospholipid syndrome (APS) patients at higher risk of a new event.
Methods
Thrombotic APS patients were followed from May 2013 to July 2017. At baseline, we measured lupus anticoagulant, IgG/IgM anticardiolipin, anti-ß2-glycoprotein I, antiphosphatidylserine-prothrombin (aPS/PT) and IgG aß2GPI-DI, and calculated GAPSS for each patient.
Results
A total of 44 patients (age 43 ± 10 years, 89% female, 73% primary APS) were followed for 39 months (range 9–46 months). Four new thromboses occurred, two of them after vitamin K antagonist interruption. Recurrent patients presented higher GAPSS (median 20) and were triple and aß2GPI-DI positive; non-recurrent patients had lower GAPSS (median 10.5, range 0–20) and lower ratio of triple (33%) and aß2GPI-DI positivities (38%). aß2GPI-DI was associated with higher GAPSS (median 19 vs. 7, p < 0.001; Pearson correlation 0.82, p < 0.001) and had a greater proportion of triple (83% vs. 4%, p < 0.001) and aPS/PT positivity (94% vs. 50%, p = 0.002).
Conclusion
Our data show a significant correlation between a validated risk score such as GAPSS and the novel antiphospholipid antibody aß2GPI-DI. Future studies are needed. However, one could speculate a role of aß2GPI-DI as a risk-stratifying tool for thrombotic events in APS.
MiyakisSLockshinMDAtsumiT, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006;
4: 295–306.
2.
CerveraRSerranoRPons-EstelGJ, et al.
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis2015;
74: 1011–1018.
3.
ErkanDYaziciYSobelRLockshinMD.Primary antiphospholipid syndrome: functional outcome after 10 years. J Rheumatol2000;
27: 2817–2821.
4.
GrikaEPZiakasPDZintzarasEMoutsopoulosHMVlachoyiannopoulosPG.Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol2012;
39: 516–523.
5.
Dall’AraFReggiaRTaraborelliM, et al.
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality. Lupus2014;
23: 1255–1258.
6.
TaraborelliMReggiaRDall’AraF, et al.
Longterm outcome of patients with primary antiphospholipid syndrome: a retrospective multicenter study. J Rheumatol2017;
44: 1165–1172.
7.
CerveraRPietteJCFontJ, et al.
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum2002;
46: 1019–1027.
8.
PengoVBiasioloAPegoraroCCucchiniUNoventaFIlicetoS.Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost2005;
93: 1147–1152.
9.
SciasciaSSannaGMurruVRocatelloDKhamashtaMABertolacciniML.GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford)2013;
52: 1397–1403.
10.
SciasciaSCuadradoMJSannaG, et al.
Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res (Hoboken)2014;
66: 1915–1920.
11.
ZuilySDe LaatBMohamedS, et al.
Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford)2015;
54: 2071–2075.
12.
SciasciaSSannaGMurruVRoccatelloDKhamashtaMABertolacciniML.The Global Anti-Phospholipid Syndrome Score in primary APS. Rheumatology (Oxford)2015;
54: 134–138.
13.
SciasciaSRadinMSannaGCecchiIRoccatelloDBertolacciniML.Clinical utility of the Global Anti-Phospholipid Syndrome Score for risk stratification: a pooled analysis. Rheumatology (Oxford)2018;
57: 661–665.
14.
Fernandez MosteirinNSaez CometLSalvador OsunaCCalvo VillasJMVelilla MarcoJ.Independent validation of the adjusted GAPSS: role of thrombotic risk assessment in the real-life setting. Lupus2017;
26: 1328–1332.
15.
OkuKAmengualOBohgakiTHoritaTYasudaSAtsumiT.An independent validation of the Global Anti-Phospholipid Syndrome Score in a Japanese cohort of patients with autoimmune diseases. Lupus2015;
24: 774–775.
16.
IversonGMVictoriaEJMarquisDM.Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A1998;
95: 15542–15546.
17.
De LaatBPengoVPabingerI, et al.
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost2009;
7: 1767–1773.
18.
IoannouYRomay-PenabadZPericleousC, et al.
In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of ß2-glycoprotein I: proof of concept. J Thromb Haemost2009;
7: 833–842.
19.
MahlerMNormanGLMeroniPLKhamashtaM.Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev2012;
12: 313–317.
20.
RadinMCecchiIRoccatelloDMeroniPLSciasciaS.Prevalence and thrombotic risk assessment of anti-β2 glycoprotein I domain I antibodies: a systematic review. Semin Thromb Hemost2018;
44: 466–474.
21.
McNeeleyPADlottJSFurieRA, et al.
Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost2001;
86: 590–595.
22.
IversonGMReddelSVictoriaEJ, et al.
Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol2002;
169: 7097–7103.
23.
De LaatBDerksenRHWMUrbanusRTDe GrootPG.IgG antibodies that recognize epitope gly40-arg43 in domain I of ß2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood2005;
105: 1540–1545.
24.
De LaatBVan BerkelMUrbanusRT, et al.
Immune responses against domain I of ß(2)-glycoprotein I are driven by conformational changes: domain I of ß(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum2011;
63: 3960–3968.
25.
MahlerMAlbesaRZohouryN, et al.
Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus2016;
25: 911–916.
26.
IwaniecTKaczorMPCelińska-LöwenhoffMPolańskiSMusiałJ.Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome. Thromb Res2017;
153: 90–94.
27.
LitvinovaEDarnigeLKirilovskyABurnelYDe LunaGDragon-DureyMA.Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol2018;
9: 2971.
28.
ZhangSWuZChenS, et al.
Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. Sci Rep2016;
6: 23839.
29.
TonelloMMattiaEDel RossT, et al.
Clinical value of anti-domain I-β2glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study. Clin Chim Acta2018;
485: 74–78.
30.
D’AgostinoRBVasanRSPencinaMJ, et al.
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation2008;
117: 743–753.
31.
Council for International Organizations of Medical Sciences.International ethical guidelines for biomedical research involving human subjects.
Geneva:
CIOMS/WHO, 2002.
32.
HarrisENGharaviAEPatelSPHughesGR, et al.
Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.Clin Exp Immunol1987;
68: 215–222.
33.
AmengualOAtsumiTKhamashtaMAKoikeTHughesGR.Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol1996;
35: 1239–1243.
34.
BrandtJTTriplettDAAlvingBScharrerI.Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost1995;
74: 1185–1190.
35.
PengoVTripodiAReberG, et al.
Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost2009;
7: 1737–1740.
36.
ZhangSWuZLiPBaiYZhangFLiY.Evaluation of the clinical performance of a novel chemiluminescent immunoassay for detection of anticardiolipin and anti-beta2-glycoprotein 1 antibodies in the diagnosis of antiphospholipid syndrome. Medicine (Baltimore)2015;
94: e2059.
37.
ForastieroRMartinuzzoMPomboG, et al.
A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost2005;
3: 1231–1238.
38.
BizzaroNGhirardelloAZampieriS, et al.
Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost2007;
5: 1158–1164.
39.
SciasciaSMurruVSannaGRoccatelloDKhamashtaMABertolacciniML.Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost2012;
10: 2512–2518.
40.
SciasciaSSannaGMurruVRoccatelloDKhamashtaMABertolacciniML.Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost2014;
111: 354–364.
41.
OtomoKAtsumiTAmengualO, et al.
Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum2012;
64: 504–512.
42.
OkuKAmengualONakamuraH, et al.
Markers of thrombotic events in autoimmune diseases: comparison of Antiphospholipid Score (aPL-S) and Global Anti-phospholipid Syndrome Score (GAPSS). J Reprod Immunol2015;
112: 129–130.
43.
BanzatoAPozziNFrassonR, et al.
Antibodies to domain I of β(2)glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res2011;
128: 583–586.
44.
MeneghelLRuffattiAGavassoS, et al.
Detection of IgG anti-domain I beta2 glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin Chim Acta2015;
446: 201–205.
45.
De CraemerASMusialJDevreeseKMJ.Role of anti-domain 1-ß2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost2016;
14: 1779–1787.
46.
NakamuraHOkuKAmengualO, et al.
First-line, non-criterial antiphospholipid antibody testing for the diagnosis of antiphospholipid syndrome in clinical practice: a combination of anti-beta2-glycoprotein I domain I and phosphatidylserine/prothrombin complex antibodies tests. Arthritis Care Res (Hoboken)2018;
70: 627–634.
47.
McdonnellTArtim-esenBWincupC, et al.
Antiphospholipid antibodies to domain I of beta-2-glycoprotein I show different subclass predominance in comparison to antibodies to whole beta-2-glycoprotein I. Front Immunol2018;
9: 2244.
48.
KhamashtaMACuadradoMJMujicF, et al.
The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med1995;
332: 993–997.
49.
CavazzanaIAndreoliLLimperMFranceschiniFTincaniA.Update on antiphospholipid syndrome: ten topics in 2017. Curr Rheumatol Rep2018;
20: 15.
50.
UnluOAndradeDBanzatoA, et al.
Antiphospholipid Syndrome Alliance for Clinical Trials & InternatiOnal Networking (APS ACTION) clinical database and repository (‘registry’) analysis: first and recurrent thrombosis risk after 1201 patient-years of follow-up. Arthritis Rheum2017;
69: 2760.
